1. Verweij J, Hendriks HR, Zwierzina H. Innovation in oncology clinical trial design. Cancer Treat Rev. 2019;74:15–20.
2. European Medicines Agency. Pharmacokinetic studies in man. 1987. https://www.ema.europa.eu/en/documents/scientific-guideline/pharmacokinetic-studies-man_en.pdf. Accessed 25 May 2019
3. European Medicines Agency. Clinical pharmacology and pharmacokinetics: questions and answers. 2019. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers. Accessed 26 May 2019
4. US FDA. Bioavailability studies submitted in NDAs or INDs—general considerations and guidance for industry. Silver Spring, MD: US FDA; 2019.
5. Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41:412–22.